Patents by Inventor Jeremy Mark Travins

Jeremy Mark Travins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20230391773
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: August 16, 2023
    Publication date: December 7, 2023
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Plasma Kallikrein inhibitors and uses thereof
    Patent number: 11787796
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20230078513
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: March 16, 2023
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20220298176
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 3, 2022
    Publication date: September 22, 2022
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 11370803
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • HETEROARYL PLASMA KALLIKREIN INHIBITORS
    Publication number: 20210079022
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF
    Publication number: 20210078999
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20200317667
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 10730874
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: August 4, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF
    Publication number: 20190284182
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 19, 2019
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, JR., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • Benzimidazole Compounds
    Publication number: 20110034526
    Abstract: This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) having formula (I) and related methods: wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R7, and (ii) optionally substituted with from 1-5 Re; and R1, R3, R4, R5, R6, R7, and Re are defined herein.
    Type: Application
    Filed: December 19, 2008
    Publication date: February 10, 2011
    Applicant: Wyeth LLC
    Inventors: Ronald Charles Bernotas, Jeremy Mark Travins, Jay Edward Wrobel, David Harry Kaufman
  • Quinazoline Compounds
    Publication number: 20100273816
    Abstract: Disclosed are quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, W, W1, W2, W3, A, Ra, Ra?, Rb, Rb?, Rc, Rd, Rd?, Re, Rf, Rg, Rh, Ri Rj, Rk, Rm, Rn, Ro, Rp, Rq, and n, can be, independently, as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    Type: Application
    Filed: May 15, 2008
    Publication date: October 28, 2010
    Inventors: Ronald Charles Bernotas, John William Ullrich, Jeremy Mark Travins, Jay Edward Wrobel, Rayomand Jal Unwalla
  • Polar Quinazolines
    Publication number: 20100184786
    Abstract: Disclosed are polar quinazoline-based modulators of Liver X receptors (LXRs) and related methods. The modulators include compounds of formula (I): in which, R1, R2, R3, R4, R5, R6, R22, R23, R24, R25, R26, R27, R28, R29, W, W1, W2, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, and n can be as defined anywhere herein. In general, these compounds can be used for treating or preventing one or more diseases, disorders, conditions or symptoms mediated by LXRs.
    Type: Application
    Filed: November 19, 2009
    Publication date: July 22, 2010
    Applicant: Wyeth LLC
    Inventors: Jeremy Mark Travins, Ronald Charles Bernotas, Jay Edward Wrobel, David Harry Kaufman, Baihua Hu, James Winfield Jetter, David John O'Neill, Charles William Mann